Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TUBB | P07437 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358854 | 0.90 | HTT (0.75) | CA1CA2ALDH1A1HTTLMNA | |
| SCHEMBL19358850 | 0.90 | CA1 (0.72) | CA1CA2GPR17MAPTMEN1 | |
| SCHEMBL19358883 | 0.86 | MAPT (0.63) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL19358841 | 0.86 | MEN1 (0.75) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL19358924 | 0.86 | MAPT (0.74) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL19358844 | 0.84 | MAPT (0.65) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL19358853 | 0.84 | TP53 (0.81) | MAPTMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL19358881 | 0.82 | HTT (0.75) | CA1CA2GPR17MAPTMEN1 | |
| SCHEMBL15953394 | 0.82 | HTT (0.79) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL19358909 | 0.81 | MAPT (0.56) | MAPTMEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429588-B1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | UNIV EMORY (US) | 2024-09-18 | — | — | EP | disclosed |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | EMORY UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | EMORY UNIVERSITY (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3429588-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | Emory University (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160832-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | EMORY UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | CXCR4, CXCL12, CXCR2 | CA1 2023/4885CA2 1700/4885GPR17 80/4885 |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | CXCR4, CXCL12, CXCR2 | CA1 2023/4885CA2 1700/4885GPR17 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.